Zacks Research Issues Positive Outlook for Omnicell Earnings

Omnicell, Inc. (NASDAQ:OMCL) – Analysts at Zacks Research raised their Q4 2024 earnings per share (EPS) estimates for Omnicell in a research note issued to investors on Thursday, January 2nd. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $0.29 for the quarter, up from their prior estimate of $0.28. The consensus estimate for Omnicell’s current full-year earnings is $0.93 per share. Zacks Research also issued estimates for Omnicell’s Q1 2025 earnings at $0.16 EPS, Q2 2025 earnings at $0.19 EPS and FY2026 earnings at $1.01 EPS.

A number of other brokerages have also issued reports on OMCL. Craig Hallum upped their target price on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Benchmark reaffirmed a “buy” rating and set a $48.00 price objective on shares of Omnicell in a report on Wednesday, October 9th. Bank of America decreased their price objective on Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research report on Monday. Barclays boosted their target price on Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Finally, JPMorgan Chase & Co. raised their price target on Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $50.17.

Omnicell Stock Down 3.0 %

Shares of NASDAQ OMCL opened at $43.37 on Monday. Omnicell has a 12-month low of $25.12 and a 12-month high of $55.74. The firm’s 50-day simple moving average is $46.25 and its 200 day simple moving average is $40.77. The company has a market cap of $2.01 billion, a price-to-earnings ratio of -111.20, a price-to-earnings-growth ratio of 34.96 and a beta of 0.78.

Hedge Funds Weigh In On Omnicell

Several institutional investors have recently modified their holdings of OMCL. Pier Capital LLC acquired a new position in shares of Omnicell in the third quarter valued at approximately $5,859,000. Royce & Associates LP acquired a new position in shares of Omnicell in the 3rd quarter valued at approximately $811,000. Federated Hermes Inc. increased its stake in Omnicell by 1,113.6% in the second quarter. Federated Hermes Inc. now owns 991,151 shares of the company’s stock valued at $26,830,000 after acquiring an additional 909,480 shares during the last quarter. Intech Investment Management LLC bought a new stake in Omnicell during the third quarter worth $753,000. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Omnicell by 750.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 294,037 shares of the company’s stock worth $12,820,000 after buying an additional 259,463 shares in the last quarter. Institutional investors own 97.70% of the company’s stock.

Insider Transactions at Omnicell

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of the business’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total value of $567,600.00. Following the completion of the transaction, the director now directly owns 58,427 shares of the company’s stock, valued at approximately $2,763,597.10. The trade was a 17.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.64% of the stock is owned by corporate insiders.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.